Argos Therapeutics to Host Review of the Current Clinical Research Landscape in Kidney Cancer Following the 40th Congress of the European Society for Medical Oncology, With Insights From Dr. Charles Drake of Johns Hopkins Sidney Kimmel Cancer Center

DURHAM, N.C., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, announced the company will host a special briefing conference call focused on the current clinical research landscape in metastatic renal cell carcinoma (mRCC). The briefing will feature Dr. Charles Drake, co-director of the division of immunology, professor of medical oncology, immunology, and urology at the Johns Hopkins Sidney Kimmel Cancer Center. The conference call is scheduled for Wednesday, October 7, 2015 at 4:30pm ET.

During the briefing, Dr. Drake will review data presented during the 40th Congress of the European Society for Medical Oncology (ESMO) held September 25-29, 2015 in Vienna, Austria, and will discuss the implications for clinical research in mRCC moving forward.

In addition to the presentation by Dr. Drake, Dr. Charles Nicolette, Argos' chief scientific officer and vice president of research and development, will also provide an update on the company's lead product candidate, AGS-003, and the pivotal ADAPT phase 3 clinical trial for the treatment of mRCC.

To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 55129797. A live and archived audio webcast can be accessed through the Investors section of the Company's website at The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About the Arcelis® Technology Platform

Arcelis® is a fully individualized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are optimized from cells collected by a single leukapheresis procedure. The proprietary process isolates RNA from the patient's disease sample to program the optimized dendritic cells to present disease specific antigens to circulating T-cells in vivo. The antigen-loaded dendritic cells are also activated with CD40L, a critical co-stimulatory factor, then combined with the patient's plasma and administered via intradermal injection, resulting in the activation, differentiation and proliferation of memory and tumor-specific killer T-cells. The high-yield process enables multiple doses to be created from a single patient cell collection.

About Argos Therapeutics

Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of 1st line, metastatic renal cell carcinoma (mRCC). The Company is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial aimed at HIV eradication in adult patients. For more information about Argos Therapeutics, visit

Forward Looking Statements

Any statements in this press release about Argos' future expectations, plans and prospects, including statements about Argos and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos' Annual Report on Form 10-K for the year ended December 31, 2014 which is on file with the SEC. In addition, the forward-looking statements included in this press release represent Argos' views as of October 5, 2015. Argos anticipates that subsequent events and developments will cause Argos' views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos' views as of any date subsequent to October 5, 2015.

CONTACT: Media contacts: Adam Daley Berry & Company Public Relations 212-253-8881 Investor contact: John Menditto Argos Therapeutics, Inc. 919-908-0687

Source:Argos Therapeutics, Inc.